Impaired skeletal development in interleukin-6-transgenic mice: A model for the impact of chronic inflammation on the growing skeletal system

Arthritis and Rheumatism

Volumn 54, Issue 11, 2006, Pages 3551-3563

  De Benedetti, Fabrizio ^a   Rucci, Nadia ^b   Del Fattore, Andrea ^b   Peruzzi, Barbara ^b   Paro, Rita ^b   Longo, Maurizio ^b   Vivarelli, Marina ^a   Muratori, Flaminia ^a   Berni, Silvia ^c   Ballanti, Paola ^c   Ferrari, Serge ^d   Teti, Anna ^b  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCENT DYE; INTERLEUKIN 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE MASS; BONE MINERAL; BONE STRUCTURE; CALVARIA; CELL ACTIVITY; CELL COUNT; CELL FUNCTION; CHRONIC INFLAMMATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; FLUORESCENCE; GENE EXPRESSION; GENE OVEREXPRESSION; GROWTH DISORDER; GROWTH PLATE; GROWTH RETARDATION; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; JUVENILE RHEUMATOID ARTHRITIS; MEASUREMENT; MINERAL APPOSITION RATE; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPENIA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETON MALFORMATION; TISSUE DIFFERENTIATION; TRABECULAR BONE; TRANSGENIC MOUSE;

ANIMALS; BONE DEVELOPMENT; BONE DISEASES, METABOLIC; CALCIFICATION, PHYSIOLOGIC; CELL DIVISION; CELLS, CULTURED; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; INTERLEUKIN-6; MICE; MICE, TRANSGENIC; OSSIFICATION, HETEROTOPIC; OSTEOBLASTS; OSTEOCLASTS; PHENOTYPE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33750953842     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22175     Document Type: Article

References (47)

1. Cassidy JT, Hillman LS. Abnormalities in skeletal growth in children with juvenile rheumatoid arthritis. Rheum Dis Clin North Am 1997;23:499-522.
2. Burnham JM, Leonard MB. Bone disease in pediatric rheumatologic disorders. Curr Rheumatol Rep 2004;6:70-8.
3. Ansell BM, Bywaters EG. Growth in Still's disease. Ann Rheum Dis 1956;15:295-319.
4. MacRae VE, Farquharson C, Ahmed SF. The pathophysiology of the growth plate in juvenile idiopathic arthritis. Rheumatology (Oxford) 2006;45:11-9.
5. Henderson CJ, Cawkwell GD, Specker BL, Sierra RI, Wilmott RW, Campaigne BN, et al. Predictors of total body bone mineral density in non-corticosteroid- treated prepubertal children with juvenile rheumatoid arthritis. Arthritis Rheum 1997;40:1967-75.
6. Lien G, Selvaag AM, Flato B, Haugen M, Vinje O, Sorskaar D, et al. A two-year prospective controlled study of bone mass and bone turnover in children with early juvenile idiopathic arthritis. Arthritis Rheum 2005;52:833-40.
7. De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I: a model for stunted growth in children with chronic inflammation. J Clin Invest 1997;15:643-50.
8. Nishimoto N, Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004;4:386-91.
9. De Benedetti F, Martini A. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? [editorial]. Arthritis Rheum 2005;52:687-93.
10. Kamimura D, Ishihara K, Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 2003;149:1-38.
11. Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A 1993;90:11924-8.
12. Franchimont N, Wertz S, Malaise M. Interleukin-6: an osteotropic factor influencing bone formation? Bone 2005;37:601-6.
13. Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 1994;13:1189-96.
14. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units: report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987;2:595-610.
15. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005;115:282-90.
16. De Benedetti F, Meazza C, Oliveri M, Pignatti P, Vivarelli M, Alonzi T, et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 2001;142:4818-26.
17. Fattori E, Lazzaro D, Musiani P, Modesti A, Alonzi T, Ciliberto G. IL-6 expression in neurons of transgenic mice causes reactive astrocytosis and increase in ramified microglial cells but no neuronal damage. Eur J Neurosci 1995;7:2441-9.
18. De Benedetti F, Pignatti P, Vivarelli M, Meazza C, Ciliberto G, Savino R, et al. In vivo neutralization of human IL-6 (hIL-6) achieved by immunization of hIL-6 transgenic mice with a hIL-6 receptor antagonist. J Immunol 2001;166:4334-40.
19. De Benedetti F, Massa M, Pignatti P, Albani S, Novick D, Martini A. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994;93:2114-9.
20. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athansou NA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003;32:1-7,
21. Lian JB, Stein JL, Stein GS, van Wijnen AJ, Montecino M, Javed A, et al. Runx2/Cbfa1 functions: diverse regulation of gene transcription by chromatin remodeling and co-regulatory protein interactions. Connect Tissue Res 2003;44 Suppl 1:141-8.
22. Hoshino K, Hanyu T, Arai K, Takahashi HE. Mineral density and histomorphometric assessment of bone changes in the proximal tibia early after induction of type II collagen-induced arthritis in growing and mature rats. J Bone Miner Metab 2001;19:76-83.
23. Kitamura H, Kawata H, Takahashi F, Higuchi Y, Furuichi T, Ohkawa H. Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice: a cellular relationship among hematopoietic cells, osteoblasts, and osteoclasts mediated by stromal cells in bone marrow. Am J Pathol 1995;147:1682-92.
24. Sims NA, Jenkins BJ, Quinn JM, Nakamura A, Glatt M, Gillespie MT, et al. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Invest 2004;113:379-89.
25. Raisz LG. Physiology and pathophysiology of bone remodeling. Clin Chem 1999;45:1353-8.
26. Davies JH, Evans BA, Gregory JW. Bone mass acquisition in healthy children. Arch Dis Child 2005;90:373-8.
27. Forriol F, Shapiro F. Bone development: interaction of molecular components and biophysical forces. Clin Orthop Relat Res 2005;432:14-33.
28. Legendre F, Dudhia J, Pujol JP, Bogdanowicz P. JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes: association with a down-regulation of SOX9 expression. J Biol Chem 2003;278:2903-12.
29. Schmid C. Insulin-like growth factors. Cell Biol Int 1995;19:445-57.
30. Kasukawa Y, Miyakoshi N, Mohan S. The anabolic effects of GH/IGF system on bone. Curr Pharm Des 2004;10:2577-92.
31. Ueland T. GH/IGF-I and bone resorption in vivo and in vitro. Eur J Endocrinol 2005;152:327-32.
32. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998;187:461-8.
33. Boe A, Baiocchi M, Carbonatto M, Papoian R, Serlupi-Crescenzi O. Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine 1999;11:1057-64.
34. De Hooge AS, van De Loo FA, Arntz OJ, van Den Berg WB. Involvement of IL-6, apart from its role in immunity, in mediating a chronic response during experimental arthritis. Am J Pathol 2000;157:2081-91.
35. Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, et al. Distinct contribution of IL-6, TNF-α, IL-1, and IL10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest 2004;114:582-8.
36. Wong PK, Quinn JM, Sims NA, van Nieuwenhuijze A, Campbell IK, Wicks IP. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum 2006;54:158-68.
37. Cezard JP, Touati G, Alberti C, Hugot JP, Brinon C, Czernichow P. Growth in paediatric Crohn's disease. Horm Res 2002;58 Suppl 1:11-5.
38. Bernstein CN, Leslie WD. The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol 2003;15:857-64.
39. Conway SP. Impact of lung inflammation on bone metabolism in adolescents with cystic fibrosis. Paediatr Respir Rev 2001;2:324-31.
40. Haworth CS, Selby PL, Webb AK, Martin L, Elborn JS, Sharpies LD, et al. Inflammatory related changes in bone mineral content in adults with cystic fibrosis. Thorax 2004;59:613-7.
41. Wine E, Reif SS, Leshinsky-Silver E, Weiss B, Shaoul RR, Shamir R, et al. Pediatric Crohn's disease and growth retardation: the role of genotype, phenotype and disease severity. Pediatrics 2004;114:1281-6.
42. Sproul A, Huang N. Growth patterns in children with cystic fibrosis. J Pediatr 1964;65:664-76.
43. Aris RM, Stephens AR, Ontjes DA, Denene Blackwood A, Lark RK, Hensler MB, et al. Adverse alterations in bone metabolism are associated with lung infection in adults with cystic fibrosis. Am J Respir Crit Care Med 2000;162:1674-8.
44. Sylvester FA, Wyzga N, Hyams JS, Gronowicz GA. Effect of Crohn's disease on bone metabolism in vitro: a role for interleukin-6. J Bone Miner Res 2002;17:695-702.
45. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005;52:818-25.
46. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126:989-96.
47. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, doubleblind, placebo-controlled trial. Arthritis Rheum 2004;50:1761-9.